skip to navigation skip to content
Search

In the media

 

Channel4.com: UK system for approving cancer drugs ‘not fit for purpose’

As patients criticise the decision not to approve breast cancer drug Kadcyla, [Executive MBA participant] Dr Rav Seeruthun, spokesman for drug company Roche, dismisses criticism of its high price, and damns the approval process.

Cambridge EMBA participant, Dr Rav Seeruthun, spokesman for drug company, Roche, defends the company’s pricing policy on breast cancer drug, Kadcyla.

Watch the video [channel4.com]